Shopping Cart
- Remove All
- Your shopping cart is currently empty
LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $32 | In Stock | |
2 mg | $45 | In Stock | |
5 mg | $72 | In Stock | |
10 mg | $122 | In Stock | |
25 mg | $197 | In Stock | |
50 mg | $372 | In Stock | |
100 mg | $556 | In Stock | |
1 mL x 10 mM (in DMSO) | $79 | In Stock |
Description | LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. |
Targets&IC50 | Tubulin polymerization:3.2 μM (EC50) |
In vitro | LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel[1]. |
In vivo | LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model[2]. |
Molecular Weight | 421.47 |
Formula | C22H19N3O4S |
Cas No. | 915412-67-8 |
Smiles | COc1cc(ccn1)C(=O)c1cc(NS(C)(=O)=O)cc(c1)-c1cccc2[nH]ccc12 |
Relative Density. | 1.391 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 22 mg/ml (52.20 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.